HCT's Q1 2026 Earnings Plunge: Operating Profit Down 71.8% YoY
Consolidated Q1 2026: Revenue KRW 24.7B (vs 25.7B in Q1 2025, -3.7%), operating profit KRW 0.4B (vs 1.4B, -71.8%), net profit attributable to parent KRW 0.02B (vs 1.07B, -98.3%). Sharp decline in profitability.
Separate: Revenue KRW 20.2B, operating profit KRW 0.96B, net profit KRW 0.63B (down 77% from KRW 2.7B in Q1 2025).
Segment: Testing & Certification operating loss of KRW 0.06B, Calibration operating profit KRW 0.95B, Other (Bio etc.) operating loss KRW 0.48B.
Financial position: Total assets KRW 183.5B, liabilities KRW 85.7B, equity KRW 97.8B. Debt ratio 87.7%, adjusted debt ratio 81.86%. Cash and cash equivalents dropped sharply to KRW 5.7B from KRW 17.2B at year-end (liquidity deterioration).
Borrowings: Total KRW 55.8B (short-term KRW 20.6B, long-term KRW 19.4B etc.). Interest coverage ratio 0.7x.
Key order: Chemical/Biological Reconnaissance Vehicle-II overhaul development (KRW 7.676B, until June 2027).
R&D: Continuous investment in automation SW, cybersecurity, AI data quality.
Shareholder return: Stock dividend of 92,000 shares in March 2026 (acquired 1,866 treasury shares from fractional shares). No cash dividend.
Credit rating: A (Korea Data) maintained.
Short-term earnings weak, but positive factors include FCC TCB, global network, expansion into battery/defense/medical devices.